Trials / Completed
CompletedNCT02720107
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod. Long-term changes in T cell counts will be compared to short-term changes in immune status (baseline to month 6) after treatment start with fingolimod as assessed in the original Biobank study (CFTY720DDE01).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fingolimod |
Timeline
- Start date
- 2016-05-12
- Primary completion
- 2016-11-14
- Completion
- 2016-11-14
- First posted
- 2016-03-25
- Last updated
- 2019-02-08
- Results posted
- 2019-02-08
Locations
26 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02720107. Inclusion in this directory is not an endorsement.